B-cell lymphoid malignancies, including chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL), the most prevalent subtypes of non-Hodgkin lymphoma (NHL), are characterized by chronic activation of the B-cell receptor (BCR) signaling [1, 2]. The gene discussed is BCR; the disease is diffuse large B-cell lymphoma.